MYGNMYRIAD GENETICS INC
In Vitro & In Vivo Diagnostic Substances
- Revenue
- $825M
- 1.6% YoY
- Operating margin
- -47.0%
- 219% YoY
- EBITDA
- −$334M
- 435% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $6M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear7% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $691M | $678M | $753M | $838M | $825M | 1.6% |
| Operating income | −$191M | −$141M | −$257M | −$124M | −$387M | 214% |
| Net income | −$27M | −$112M | −$263M | −$127M | −$366M | 188% |
| Operating cash flow | $19M | −$106M | −$111M | −$9M | $2M | 121% |
| Capex | $18M | $45M | — | — | — | |
| Stock-based comp | $36M | $38M | $41M | $50M | $35M | 29% |
| Buybacks | $0 | — | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 31 | 125 |
| FY2024 | $14M | $7M | 69 | 93 |
| FY2023 | $12M | $14M | 97 | 94 |
| FY2022 | $11M | −$4M | 73 | 90 |
| FY2021 | $13M | $30M | 140 | 100 |